Molecular stabilities, conformational analyses and molecular docking studies of benzimidazole derivatives bearing 1,2,4-triazole as EGFR inhibitors

被引:0
作者
Arzu Karayel
机构
[1] University of Hitit,Faculty of Arts and Sciences, Department of Physics
来源
Structural Chemistry | 2021年 / 32卷
关键词
Benzimidazole bearing 1,2,4-triazole; Thione-thiol tautomerism; EGFR; DFT; Molecular docking; Conformational analysis;
D O I
暂无
中图分类号
学科分类号
摘要
A detailed study of the tautomeric properties, the conformations, and the mechanism behind the anti-cancer properties of 5-{[2-(4-methoxyphenyl)-1H-benzimidazol-1-yl]methyl}-4-ethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (1), 2-(4-chlorophenyl) (2), 2-phenyl (3), 2-(3,4-dibenzyloxyphenyl) (4), and 2-(4-methoxyphenyl); 4-[2-(piperidin-1-yl)ethyl] (5) has been conducted using density functional theory and molecular docking. The most stable states of all the structures are shown to be in the thione form. The scans of the compounds point out two conformers at PES, one of two conformers for molecule 1 corresponds to X-ray geometry, being the lowest energy state. Current molecules (1, 2, 3, and 5) have one inter-molecular hydrogen bond between NH atom of triazole ring and =O atom in residue ARG817 of the EGFR binding pocket, while compound 4 has different type inter-molecular hydrogen bond which is between N atom in benzimidazole ring and H atom of NH3 in residue LYS721. Off all hydrogen bonds, that of 5 is the strongest one with 2.26 Å. Compound 4 has shown the best binding affinity with −10.0 kcal/mol. This compound is the most active compound regarding to the potential anti-cancer activity.
引用
收藏
页码:1247 / 1259
页数:12
相关论文
共 165 条
  • [1] Normanno N(2006)Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2-16
  • [2] De Luca A(2007)Rational bases for the development of EGFR inhibitors for cancer treatment Int J Biochem Cell Biol 39 1416-1431
  • [3] Bianco C(2011)Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR) Med Chem 7 24-31
  • [4] Strizzi L(2014)Synthesis and biological evaluation of 1-cyano-2-amino-benzimidazole derivatives as a novel class of antitumor agents Med Chem Res 23 3029-3038
  • [5] Mancino M(2009)Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles Eur J Med Chem 44 1808-1812
  • [6] Maiello MR(2017)Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors Eur J Med Chem 126 853-869
  • [7] Carotenuto A(2018)Synthesis and anticancer activity of novel water soluble benzimidazole carbamates Eur J Med Chem 144 372-385
  • [8] De Feo G(2019)Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors Eur J Med Chem 173 240-249
  • [9] Caponigro F(2011)Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors Bioorg Med Chem 19 4529-4535
  • [10] Salomon DS(2008)Synthesis and antioxidant properties of novel N-methyl-1,3,4-thiadiazol-2-amine and 4-methyl-2H-1,2,4-triazole-3(4H)-thione derivatives of benzimidazole class Bioorg Med Chem 16 4294-4303